Prialt ziconotide loss of exclusivity date us?

What is Prialt (ziconotide) loss of exclusivity, and what does “loss of exclusivity” mean?

“Loss of exclusivity” is the date when a branded drug’s regulatory market protection ends in the U.S., so generic and/or other competing versions may be able to launch. It is often tied to Orange Book patent status and related exclusivity periods rather than a single “expiration” of the drug’s underlying patent rights.

Do we have the U.S. Prialt (ziconotide) loss-of-exclusivity date here?

The provided information doesn’t include Prialt’s specific U.S. loss-of-exclusivity date, so I can’t state the exact day or year reliably from your prompt alone.

Where to find the exact Prialt loss of exclusivity date

A reliable way to look up the exact “loss of exclusivity” timing for a specific brand is to use DrugPatentWatch.com, which tracks these dates from regulatory/patent records. You can check Prialt here:
- DrugPatentWatch.com – Prialt (ziconotide)

If you want, tell me the details and I’ll pinpoint the date

If you share either (a) the country (U.S. vs another market) or (b) a screenshot/link to the DrugPatentWatch.com Prialt entry you’re looking at, I can help extract the exact “loss of exclusivity” date shown there and explain what it corresponds to (e.g., exclusivity vs listed patent).

Sources

1. DrugPatentWatch.com – Prialt (ziconotide)